[PDF] Top 20 Trabajo de La Fundación de Antonio Buero Vallejo
Has 10000 "Trabajo de La Fundación de Antonio Buero Vallejo" found on our website. Below are the top 20 most common "Trabajo de La Fundación de Antonio Buero Vallejo".
Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets
... underlying T cell exhaustion revealed that exhausted T cells have a transcriptional profile with major alterations in the expression of inhibitory receptors, cytokine and che- mokine receptors, ... See full document
14
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
... humoral immunity to galectin-1 may contribute to the efficacy of anti-VEGF (bevacizumab) and anti-CTLA-4 (ipilimumab) combin- ation therapy [189], offering an additional therapeutic target linking ... See full document
8
New Strategies for the Treatment of Solid Tumors with CAR-T Cells
... novel therapeutic strategies with genetically engineered T ...endows T cells with tumor specific cytotoxicity and thus induce anti-tumor immunity against ...However, targeting solid ... See full document
8
New emerging targets in cancer immunotherapy: CD27 (TNFRSF7)
... in T- cell activation by providing a costimulatory ...enhances T- cell proliferation and differentiation to effector and memory T cells and therefore has potential as an immune ... See full document
27
New therapeutic targets for cancer: the interplay between immune and metabolic checkpoints and gut microbiota
... and T lymphocyte attenuator; CAF: cancer associated fibroblasts; CEA: carcinoembryonic antigen; CSC: cancer stem cell; CSCC: cutaneous squamous cell carcinoma; CT: cytoplasmic tail; ... See full document
11
Targeting T cell metabolism in the tumor microenvironment: an anti-cancer therapeutic strategy
... + T cells. When T cells are activated, lipid mediators and cytokines promote T-cell migration, proliferation, and differentiation [11, ...+ T cells. Upon CD8 + T cell ... See full document
112
BIOSYNTHETIC PATHWAY AND MOLECULAR DOCKING OF METHYL ISOCYANATE (MIC) - p53 INTERACTION STUDY
... The regions involved in the interaction between p53 and MDM2 is the MDM2-binding domain on p53 and have residues between 1 and 52. The other is the p53-binding domain having residues between 1 and 118. The MDM2 acts as ... See full document
9
Click here to download PDF version of the article !
... intrinsic mechanism and extracellular signals which are derived from specialised microenvironment ...of cancer cells in the tumour specific premetastatic ...that targeting the CSC niche produced more ... See full document
86
Myeloid derived suppressor cells in the tumor microenvironment: expect the unexpected
... in cancer patients ...different cancer types. This issue and the role MDSCs play in cancer prognosis have recently been reviewed for a number of tumor types ...of cancer patients is now well ... See full document
141
New emerging targets in cancer immunotherapy: the role of LAG3
... Due to the success gained by the dual blockage of CTLA4 and PD-(L)1, new approaches for single immunothera- pies, which might enhance their efficacy are established. In the last few years, LAG3 has gained ... See full document
12
New emerging targets in cancer immunotherapy: the role of TIM3
... effector T cell and galectin-9 on a tumour cell inhibits the immune response by inducing apoptosis in the T ...effector T cell function. Blocking Tim3 with a mAb thus ... See full document
74
Breast cancer causes and treatment: where are we going wrong?
... relation to the breast, it is part of the reproductive system, and is unique in that it only becomes fully formed in early life after puberty. Breast tissue changes with hormonal fluctua- tion during the menstrual cycle ... See full document
71
Cancer Immunotherapy and Flow Cytometry in Immunotherapy Monitoring
... of T cells to prevent alloreactivity and to prevent damage of lymphocytes through host versus graft (HvG) ...reactions. T-cell engineering includes lentiviral transduction for CAR expression followed ... See full document
10
NOTCH 1 and NOTCH 4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications
... hexamers using the MultiScribe™ Reverse Transcriptase Kit (Applied Biosystems, Foster City, CA, USA) accord- ing to the manufacturer’s protocol. Analysis of transcript relative fold copy number adjusted to hypoxanthine- ... See full document
11
Cancer Immunoprevention and Public Health
... the immune enhancement and cancer prevention is not known as ...on cancer preven- tion although this is not exclusively due to immune-enhancing effects (90, ...in cancer prevention ... See full document
20
A novel peptide targeting Clec9a on dendritic cell for cancer immunotherapy
... Clec9a binding peptides screening and validating It was reported that the C-type lectin-like domain (CTLD) of Clec9a was important to the antigen recognition and endocytosis. Therefore, bio-panning was performed by using ... See full document
7
Anti–PD 1/PD L1 therapy of human cancer: past, present, and future
... activated T cells (17) and also stimulates IL-10 pro- duction in human peripheral blood T cells (4) to mediate immune ...on immune suppression are far more complicated. In addition to T ... See full document
12
Targeting adenosine for cancer immunotherapy
... other immune checkpoint inhibitors has been established in preclinical studies and evaluation in clinical studies has ...stream targeting of both the A2aR and CD73 has been shown to be efficacious in ... See full document
40
Original Article Correlation between cellular immune function and prognosis of gastric cancer
... Gastric cancer is one of the most common can- cers that derived from epithelial malignant tumors, namely gastric adenocarcinoma, which accounts for 95% of the malignant gastric tumors ...Gastric cancer is ... See full document
71
Targeting immune checkpoints in breast cancer: an update of early results
... provides new strategies for the treatment of a variety of neoplastic diseases, including BC, with promising results already demonstrated in the TN subtype in the advanced and neoadjuvant ...of immunotherapy ... See full document
21
Related subjects